Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (171-180 of 271) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerToni K Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, et al.
ESMO Open|November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trialsAndrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Nature Medicine|August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology|April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 studyRamaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.
Urologic Oncology|February 22, 2015
Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intentMegan M Merrill, Christopher G Wood, Nizar M Tannir, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 31, 2015
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific deathThai H Ho, Payal Kapur, Richard W Joseph, et al.
European Urology|August 1, 2025
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk FactorsAlessandro Larcher, Riccardo Campi, Axel Bex, et al.
Clinical Genitourinary Cancer|February 21, 2017
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy EraSarathi Kalra, Jonathan Verma, Bradley J Atkinson, et al.
Science Translational Medicine|October 27, 2021
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancersDaniel J McGrail, Patrick G Pilié, Hui Dai, et al.
Cancers|May 5, 2021
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary CarcinomaAndrew J Wiele, Devaki Shilpa Surasi, Priya Rao, et al.
Pageof 28

Showing results (171-180 of 271) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerToni K Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, et al.
ESMO Open|November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trialsAndrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Nature Medicine|August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology|April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 studyRamaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.
Urologic Oncology|February 22, 2015
Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intentMegan M Merrill, Christopher G Wood, Nizar M Tannir, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 31, 2015
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific deathThai H Ho, Payal Kapur, Richard W Joseph, et al.
European Urology|August 1, 2025
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk FactorsAlessandro Larcher, Riccardo Campi, Axel Bex, et al.
Clinical Genitourinary Cancer|February 21, 2017
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy EraSarathi Kalra, Jonathan Verma, Bradley J Atkinson, et al.
Science Translational Medicine|October 27, 2021
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancersDaniel J McGrail, Patrick G Pilié, Hui Dai, et al.
Cancers|May 5, 2021
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary CarcinomaAndrew J Wiele, Devaki Shilpa Surasi, Priya Rao, et al.
Pageof 28